Dystonia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Dystonia – Pipeline Review, H2 2016’, provides an overview of the Dystonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dystonia

The report reviews pipeline therapeutics for Dystonia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dystonia therapeutics and enlists all their major and minor projects

The report assesses Dystonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dystonia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dystonia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Advicenne SA

EpiVax, Inc.

Ipsen S.A.

Revance Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Dystonia Overview 6

Therapeutics Development 7

Pipeline Products for Dystonia - Overview 7

Pipeline Products for Dystonia - Comparative Analysis 8

Dystonia - Therapeutics under Development by Companies 9

Dystonia - Therapeutics under Investigation by Universities/Institutes 10

Dystonia - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Dystonia - Products under Development by Companies 13

Dystonia - Products under Investigation by Universities/Institutes 14

Dystonia - Companies Involved in Therapeutics Development 15

Addex Therapeutics Ltd 15

Advicenne SA 16

EpiVax, Inc. 17

Ipsen S.A. 18

Revance Therapeutics, Inc. 19

Dystonia - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

abobotulinumtoxin A - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

dipraglurant ER - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

onabotulinumtoxinA - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

RT-002 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

tetrabenazine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Dystonia - Dormant Projects 39

Dystonia - Product Development Milestones 40

Featured News & Press Releases 40

Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 40

Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study 41

Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia 43

Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved “Botox” 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for Dystonia, H2 2016 7

Number of Products under Development for Dystonia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Dystonia – Pipeline by Addex Therapeutics Ltd, H2 2016 15

Dystonia – Pipeline by Advicenne SA, H2 2016 16

Dystonia – Pipeline by EpiVax, Inc., H2 2016 17

Dystonia – Pipeline by Ipsen S.A., H2 2016 18

Dystonia – Pipeline by Revance Therapeutics, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Dystonia – Dormant Projects, H2 2016 39

List of Figures

List of Figures

Number of Products under Development for Dystonia, H2 2016 7

Number of Products under Development for Dystonia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports